IMBRAVE150

NCT03434379 📎

Regimen

Experimental
atezolizumab + bevacizumab
Control
sorafenib

Population

Unresectable hepatocellular carcinoma, no prior systemic therapy

Key finding

Primary analysis: mOS NR vs 13.2 mo (HR 0.58, 95% CI 0.42-0.79, p<0.001); mPFS 6.8 vs 4.3 mo (HR 0.59, p<0.001); 12-mo OS 67.2% vs 54.6%; updated analysis (J Hepatol 2022, PMID 34902530): mOS 19.2 vs 13.4 mo (HR 0.66); etiology reported: HBV ~49%, HCV ~21%, non-viral ~30%

Source: PMID 32402160

Timeline

    Guideline citations

    • NCCN HCC (p.28)